Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7211156 | 0.86 | KMT2A (0.43) | ALDH1A1L3MBTL1MEN1KMT2ASTAT3 | |
| SCHEMBL9016703 | 0.84 | MAPT (0.41) | ALDH1A1L3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL4510744 | 0.79 | TSHR (0.57) | ALDH1A1L3MBTL1LMNATSHRCASP1 | |
| SCHEMBL2001481 | 0.78 | TSHR (0.52) | ALDH1A1L3MBTL1LMNAKMT2ATSHR | |
| SCHEMBL2384845 | 0.76 | ALDH1A1 (0.52) | ALDH1A1L3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL31057346 | 0.76 | ALDH1A1 (0.52) | ALDH1A1L3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL4508521 | 0.75 | MAPT (0.52) | ALDH1A1L3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL3606905 | 0.75 | MEN1 (0.47) | ALDH1A1L3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL27213906 | 0.74 | CA12 (0.47) | ALDH1A1L3MBTL1LMNAKMT2ATSHR | |
| SCHEMBL4519444 | 0.74 | CTSK (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825199-B2 | 7-Substituted quinazolin-2,4-diones useful as antibacterial agents | WARNER-LAMBERT COMPANY | 2004-11-30 | — | — | US | disclosed |
| US-6696452-B2 | GLYCOGEN SYNTHASE KINASE-3 AND AURORA-2 A SERINE/THREONINE PROTEIN KINASE INHIBITORS; ANTIDIABETIC AND ANTICANCER AGENTS AND ALZHEIMER'S DISEASE TREATMENTS | VERTEX PHARMACEUTICALS INCORPORATED | 2004-02-24 | — | — | US | disclosed |
| US-6613776-B2 | Protein serine/threonine kinase inhibitors used for treating diseases such as cancer, diabetes and Alzheimer's disease | VERTEX PHARMACEUTICALS INCORPORATED | 2003-09-02 | — | — | US | disclosed |
| EP-1318814-A2 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2003-06-18 | — | — | EP | disclosed |
| EP-1028950-B1 | 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS | WARNER LAMBERT CO (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20030078166-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-24 | — | — | US | disclosed |
| US-20030064981-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-03 | — | — | US | disclosed |
| US-20020115674-A1 | Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents | DOMAGALA JOHN MICHAEL (US) | 2002-08-22 | — | — | US | disclosed |
| WO-2002022602-A2 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-03-21 | — | — | WO | disclosed |
| US-6331538-B1 | TREATMENT OF BACTERIAL INFECTION | WARNER-LAMBERT COMPANY | 2001-12-18 | — | — | US | disclosed |
| EP-1028950-A1 | NOVEL 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999021840-A1 | NOVEL 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064981-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3A | ALDH1A1 4461/4885L3MBTL1 3055/4885LMNA 2620/4885 |
| US-20020115674-A1 | Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents | NQO2, TOP1, TOP2A | ALDH1A1 3064/4885L3MBTL1 4814/4885LMNA 3642/4885 |
| US-20030078166-A1 | Pyrazole compounds useful as protein kinase inhibitors | GSK3B, GSK3A, GSKIP | ALDH1A1 4581/4885L3MBTL1 3615/4885LMNA 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.